Patients being treated with Humira (adalimumab) in British Columbia will soon be switched to adalimumab biosimilars, after the Canadian province expanded its biosimilar switching program to cover the blockbuster biologic.
Almost two years ago, British Columbia launched its biosimilar switching program that saw patients being treated with etanercept, infliximab and...